×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Merck completes Harpoon Therapeutics acquisition
Pharmaceutical Technology
Merck & Co. (MSD) has concluded the acquisition of Harpoon Therapeutics to broaden its oncology pipeline.
2 months ago
Merck to buy Harpoon Therapeutics for $680 million
Reuters
Merck & Co said on Monday it would buy cancer drug developer Harpoon Therapeutics for about $680 million, reinforcing its oncology portfolio...
4 months ago
Merck to Buy Harpoon for Cancer Drug in $680 Million Deal
Bloomberg.com
Merck & Co. has agreed to acquire cancer drugmaker Harpoon Therapeutics Inc. for $680 million as it seeks to solidify its leadership...
4 months ago
Merck Buys Harpoon Therapeutics To Expand Its Oncology Portfolio
Investopedia
Merck & Co. said Monday that it would purchase Harpoon Therapeutics Inc. for about $680 million to expand its reach in cancer-fighting...
4 months ago
Harpoon Therapeutics, Inc. (HARP) Reports Q1 Loss, Misses Revenue Estimates
Yahoo News Singapore
Harpoon Therapeutics, Inc. (HARP) delivered earnings and revenue surprises of -29.17% and 47.76%, respectively, for the quarter ended March...
1 week ago
Merck to Acquire Harpoon Therapeutics in Deal Valued at $680 Million
PharmTech
Through the acquisition of Harpoon Therapeutics, Merck will gain an investigational delta-like ligand 3-targeting T-cell engager under...
4 months ago
Merck completes acquisition of Harpoon Therapeutics
ROI-NJ
Rahway-based Merck on Monday said it completed the previously announced acquisition of Harpoon Therapeutics Inc. Harpoon is now a wholly...
2 months ago
Merck To Acquire Harpoon Therapeutics In $680M Deal
Contract Pharma
Includes HPN328, an investigational DLL3 targeting T-cell engager in development for small cell lung cancer and neuroendocrine tumors.
4 months ago
Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline
Business Wire
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. (Nasdaq: HARP) today announced that...
4 months ago
Merck in talks to buy Harpoon Therapeutics for around $700 mln - Bloomberg News
Reuters
Merck & Co is in advanced talks to buy cancer drugmaker Harpoon Therapeutics Inc for around $700 million, Bloomberg News reported on Sunday,...
4 months ago